These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20405969)

  • 21. Place of care and costs associated with acute episodes and remission in bipolar I disorder.
    McIntyre RS; Higa S; Doan QV; Amari D; Oliveri D; Gillard P; Harrington A
    J Med Econ; 2022; 25(1):1110-1117. PubMed ID: 36082506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic management of bipolar disorder in France and Europe: a multinational longitudinal study (WAVE-bd)].
    Bellivier F; Delavest M; Coulomb S; Figueira ML; Langosch JM; Souery D; Vieta E
    Encephale; 2014 Oct; 40(5):392-400. PubMed ID: 25238903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed states with predominant manic or depressive symptoms: baseline characteristics and 24-month outcomes of the EMBLEM cohort.
    Azorin JM; Baraille L; Gérard S; Bertsch J; Reed C; Lukasiewicz M
    J Affect Disord; 2013 Apr; 146(3):369-77. PubMed ID: 23089130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication.
    Azorin JM; Aubrun E; Bertsch J; Reed C; Gerard S; Lukasiewicz M
    BMC Psychiatry; 2009 Jun; 9():33. PubMed ID: 19500417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).
    Gonzalez-Pinto A; Vieta E; Reed C; Novick D; Barraco A; Aguado J; Haro JM
    J Affect Disord; 2011 Jun; 131(1-3):320-9. PubMed ID: 21195486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty.
    Keating JF; Grant A; Masson M; Scott NW; Forbes JF
    Health Technol Assess; 2005 Oct; 9(41):iii-iv, ix-x, 1-65. PubMed ID: 16202351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
    Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
    Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.
    Standaert B; Goldstone J; Lu ZJ; Erder MH; Yin JL
    Pharmacoeconomics; 2002; 20(10):665-74. PubMed ID: 12162755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic mania revisited: factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM).
    Van Riel WG; Vieta E; Martinez-Aran A; Haro JM; Bertsch J; Reed C; Van Os J
    World J Biol Psychiatry; 2008; 9(4):313-20. PubMed ID: 18949649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
    Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
    Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bipolar disorder in Spain: functional status and resource use on the basis of the Spanish sample of the observational, Pan European EMBLEM study].
    Montoya A; Gilaberte I; Costi M; Pérez Sánchez Toledo J; González Pinto A; Ma Haro J; Comes M; Vieta E
    Vertex; 2007; 18(71):13-9. PubMed ID: 17356717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of nurse led intermediate care versus standard care for post-acute medical patients: cost minimisation analysis of data from a randomised controlled trial.
    Walsh B; Steiner A; Pickering RM; Ward-Basu J
    BMJ; 2005 Mar; 330(7493):699. PubMed ID: 15757959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive deficits in bipolar disorders: Implications for emotion.
    Lima IMM; Peckham AD; Johnson SL
    Clin Psychol Rev; 2018 Feb; 59():126-136. PubMed ID: 29195773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy.
    Bellantuono C; Barraco A; Rossi A; Goetz I
    BMC Psychiatry; 2007 Jul; 7():33. PubMed ID: 17640381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France.
    de Zelicourt M; Dardennes R; Verdoux H; Gandhi G; Khoshnood B; Chomette E; Papatheodorou ML; Edgell ET; Even C; Fagnani F
    Pharmacoeconomics; 2003; 21(15):1081-90. PubMed ID: 14596627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National estimates of the inpatient burden of pediatric bipolar disorder in the United States.
    Berry EA; Heaton PT; Kelton CM
    J Ment Health Policy Econ; 2011 Sep; 14(3):115-23. PubMed ID: 22116169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.